BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/20/2020 4:04:17 AM | Browse: 874 | Download: 1543
 |
Received |
|
2020-07-16 14:32 |
|
Peer-Review Started |
|
2020-07-16 14:32 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-14 05:53 |
|
Revised |
|
2020-09-27 21:06 |
|
Second Decision |
|
2020-10-16 11:47 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-10-20 04:19 |
|
Articles in Press |
|
2020-10-20 04:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-19 01:09 |
|
Publish the Manuscript Online |
|
2020-11-20 04:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Cristina Maria Muzica, Carol Stanciu, Laura Huiban, Ana-Maria Singeap, Catalin Sfarti, Sebastian Zenovia, Camelia Cojocariu and Anca Trifan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Anca Trifan, FRCP (C), MD, PhD, Doctor, Doctor, Professor, Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, St. Spiridon Emergency Hospital, University Street 16, Iasi 700115, Romania. ancatrifan@yahoo.com |
| Key Words |
Hepatocellular carcinoma; Direct acting antivirals therapy; Hepatitis C virus infection; Sustained virological response; Risk factors of hepatocellular carcinoma; Review |
| Core Tip |
The risk of hepatocellular carcinoma (HCC) occurrence or recurrence in patients with chronic hepatitis C virus (HCV) infection receiving direct acting antivirals (DAAs) has been debated through the last 4 years. Data provided by current literature indicate a decreasing incidence rate of HCC (both de novo and recurrent) in patients with chronic hepatitis C, HCV-related cirrhosis, and HCV-related HCC after achieving sustained virological response with DAAs. |
| Publish Date |
2020-11-20 04:04 |
| Citation |
Muzica CM, Stanciu C, Huiban L, Singeap AM, Sfarti C, Zenovia S, Cojocariu C, Trifan A. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end. World J Gastroenterol 2020; 26(43): 6770-6781 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i43/6770.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i43.6770 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
